Targetable genetic alterations of


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
19 06 2019
Historique:
received: 28 09 2018
revised: 31 01 2019
accepted: 15 05 2019
entrez: 21 6 2019
pubmed: 21 6 2019
medline: 1 7 2020
Statut: ppublish

Résumé

The activated B cell (ABC-like) subtype of diffuse large B cell lymphoma (DLBCL) is characterized by chronic activation of signaling initiated by immunoglobulin μ (IgM). By analyzing the DNA copy number profiles of 1000 DLBCL tumors, we identified gains of 18q21.2 as the most frequent genetic alteration in ABC-like DLBCL. Using integrative analysis of matched gene expression profiling data, we found that the

Identifiants

pubmed: 31217338
pii: 11/497/eaav5599
doi: 10.1126/scitranslmed.aav5599
pmc: PMC6724184
mid: NIHMS1047498
pii:
doi:

Substances chimiques

Immunoglobulins 0
TCF4 protein, human 0
Transcription Factor 4 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : R01 CA210250
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA191222
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197566
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA201380
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA036727
Pays : United States

Informations de copyright

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Références

Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
Nat Rev Immunol. 2001 Dec;1(3):193-9
pubmed: 11905828
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6
pubmed: 12900505
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Nat Genet. 2006 May;38(5):500-1
pubmed: 16642009
DNA Res. 2006 Jun 30;13(3):123-34
pubmed: 16980320
Blood. 2007 Jul 1;110(1):29-36
pubmed: 17360935
Science. 2008 Mar 21;319(5870):1676-9
pubmed: 18323416
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5
pubmed: 18765795
N Engl J Med. 2008 Nov 27;359(22):2313-23
pubmed: 19038878
Nature. 2009 Jun 4;459(7247):712-6
pubmed: 19412163
Nature. 2009 Jun 4;459(7247):717-21
pubmed: 19412164
Nature. 2010 Jan 7;463(7277):88-92
pubmed: 20054396
Blood. 2010 Oct 28;116(17):3268-77
pubmed: 20628145
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Br J Haematol. 2010 Nov;151(3):221-31
pubmed: 20813005
Nature. 2011 Feb 3;470(7332):115-9
pubmed: 21179087
Leukemia. 2011 Apr;25(4):681-8
pubmed: 21233831
Genes Chromosomes Cancer. 2011 May;50(5):313-26
pubmed: 21305641
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Nature. 2011 Jul 27;476(7360):298-303
pubmed: 21796119
Nat Genet. 2011 Jul 31;43(9):830-7
pubmed: 21804550
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Hum Mol Genet. 2012 Jul 1;21(13):2873-88
pubmed: 22460224
Nature. 2012 Oct 4;490(7418):116-20
pubmed: 22885699
Nat Genet. 2012 Oct;44(10):1104-10
pubmed: 22941188
Cancer Cell. 2012 Sep 11;22(3):359-72
pubmed: 22975378
Nat Genet. 2012 Dec;44(12):1316-20
pubmed: 23143595
Cytogenet Genome Res. 2013;139(2):80-7
pubmed: 23182917
Cancer Cell. 2013 May 13;23(5):677-92
pubmed: 23680150
Blood. 2013 Oct 10;122(15):2673-82
pubmed: 24004666
Nat Rev Clin Oncol. 2014 Jan;11(1):12-23
pubmed: 24217204
Cancer Cell. 2013 Dec 9;24(6):777-90
pubmed: 24332044
Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11365-70
pubmed: 25049379
Clin Cancer Res. 2015 Apr 1;21(7):1628-38
pubmed: 25623213
Chem Biol. 2015 Jun 18;22(6):755-63
pubmed: 26051217
Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13447-54
pubmed: 26483459
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Nat Biotechnol. 2016 May;34(5):539-46
pubmed: 27088724
J Exp Med. 2016 May 30;213(6):1095-111
pubmed: 27217539
J Exp Med. 2016 Jun 27;213(7):1201-21
pubmed: 27261530
Cancer Cell. 2016 Nov 14;30(5):764-778
pubmed: 27846392
Cancer Res. 2017 Jun 1;77(11):2976-2989
pubmed: 28416490
Blood. 2017 Aug 24;130(8):995-1006
pubmed: 28646116
Leukemia. 2018 Feb;32(2):343-352
pubmed: 28663582
J Exp Med. 2017 Sep 4;214(9):2759-2776
pubmed: 28701369
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
Blood. 2017 Oct 19;130(16):1819-1831
pubmed: 28801451
Leukemia. 2018 Mar;32(3):675-684
pubmed: 28804123
Blood. 2018 Feb 8;131(6):595-604
pubmed: 29158360
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Cancer Discov. 2018 Jan;8(1):24-36
pubmed: 29263030
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Nature. 2018 Aug;560(7718):387-391
pubmed: 29925955

Auteurs

Neeraj Jain (N)

Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Keenan Hartert (K)

Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Saber Tadros (S)

Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Warren Fiskus (W)

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Ondrej Havranek (O)

Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Man Chun John Ma (MCJ)

Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Alyssa Bouska (A)

Department of Pathology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Tayla Heavican (T)

Department of Pathology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Dhiraj Kumar (D)

Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Qing Deng (Q)

Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Dalia Moore (D)

Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Christine Pak (C)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Chih Long Liu (CL)

Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.

Andrew J Gentles (AJ)

Department of Radiology, Stanford University, Stanford, CA 94305, USA.

Elena Hartmann (E)

Institute of Pathology, University of Würzburg, Würzburg 97080, Germany.
Comprehensive Cancer Center Mainfranken, Wurzburg 97080, Germany.

Robert Kridel (R)

Princess Margaret Cancer Center, University of Toronto, Toronto, ON M5G 2C4, Canada.

Karin Ekstrom Smedby (KE)

Department of Medicine, Solna, Clinical Epidemiology Unit, Karolinska Institutet, and Hematology Center, Karolinska University Hospital, Stockholm SE-171 76, Sweden.

Gunnar Juliusson (G)

Department of Laboratory Medicine, Stem Cell Center, Lund University, Lund SE-221 00, Sweden.

Richard Rosenquist (R)

Department of Molecular Medicine and Surgery, Karolinska Universitetssjukhuset, Stockholm SE-171 76, Sweden.

Randy D Gascoyne (RD)

Center for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada.

Andreas Rosenwald (A)

Institute of Pathology, University of Würzburg, Würzburg 97080, Germany.
Comprehensive Cancer Center Mainfranken, Wurzburg 97080, Germany.

Filippo Giancotti (F)

Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Sattva S Neelapu (SS)

Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Jason Westin (J)

Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Julie M Vose (JM)

Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Matthew A Lunning (MA)

Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Timothy Greiner (T)

Department of Pathology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Scott Rodig (S)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Javeed Iqbal (J)

Department of Pathology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Ash A Alizadeh (AA)

Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.

R Eric Davis (RE)

Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Kapil Bhalla (K)

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Center for Cancer Epigenetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Michael R Green (MR)

Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. mgreen5@mdanderson.org.
Center for Cancer Epigenetics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH